GlassScriptPhysician profile
Gregory A Poland
NPI 1306824750
$493,542.50
in general payments reported to CMS, 2019-2025
16 companies · $43K in 2025
The $43K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63K · 2020: $106K · 2021: $147K · 2022: $30K · 2023: $63K · 2024: $42K · 2025: $43K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $146K · Travel and Lodging: $1,348 · Food and Beverage: $337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $145,988.43 |
| Travel and Lodging | $1,347.93 |
| Food and Beverage | $337.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $164,265.83 | 2019-2025 | Capvaxive |
| Glaxosmithkline, LLC. | $84,571.89 | 2019-2025 | |
| Janssen Research & Development, LLC | $57,375.00 | 2021 | |
| Sanofi Pasteur INC. | $37,503.02 | 2019-2024 | |
| Modernatx, INC. | $36,189.53 | 2022-2025 | Mresvia |
| Janssen Global Services, LLC | $21,840.00 | 2020-2022 | |
| Dynavax Technologies Corporation | $20,125.00 | 2019-2022 | |
| Emergent Biosolutions INC. | $16,850.00 | 2020-2023 | |
| Valneva USA, INC. | $12,600.00 | 2022 | |
| Bavarian Nordic A/S | $9,959.00 | 2020-2025 | |
| Genentech, INC. | $9,370.73 | 2019-2020 | |
| Astrazeneca Uk Limited | $8,750.00 | 2020-2021 | |
| Exelixis INC. | $4,900.00 | 2021 | |
| Regeneron Pharmaceuticals, INC. | $4,585.00 | 2021-2022 | |
| Lilly USA, LLC | $3,750.00 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novavax INC | $907.50 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Poland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.